Powerful perspectives

Industry Insight
Scientific innovation in uveal melanoma

Industry Insight
Opportunities and challenges in oncology immunotherapy

Industry Insight
Reflections from our CEO

Industry Insight
Pancreatic cancer – our commitment to scientific advances

Industry Insight
A bold new era in global cancer drug discovery

Industry Insight
A note from our CEO

Industry Insight
Realising the potential of autotaxin therapy in cancer

Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors

Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles

Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I First in Human (FIH) study

iOnctura announces publication of pioneering research describing the unique biological features of roginolisib

Characterization of the non-ATP competitive PI3Kδ inhibitor IOA-244 in lymphoma models: from single agent to combination screen and clinical investigation

iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program

iOnctura awarded EUR17.5 million funding from the EIC accelerator for clinical development of novel pancreatic cancer therapy

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

Safety and clinical activity of IOA-244, a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I first in human (FIH) study (study part A)

IOA-244 is a non-ATP-competitive, highly-selective, tolerable phosphoinositide-3-linase delta inhibitor that directly targets solid tumors and breaks immune tolerance

Non-ATP competitive inhibition of PI3δ with IOA-244 shows anti-lymphoma activity

iOnctura expands Advisory Board

Safety, pharmacokinetic (PK), pharmacodynamic (PD) and activity of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with follicular lymphoma (FL)

First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer

Looking for media
resources?